Objectives
- Make available state-of-art technology for improved diagnosis, thus giving valuable and economic healthcare solutions, having implications in treatment planning - pertaining to India
- Make available clinically relevant, highly sensitive, accurate, need-based and cost-effective tests
- Cater to the needs of National and International clients in the execution of customised projects
- Provide authentic, competent and value-added solutions in the use of commercially available kits (for Internal and External use)
- Create scientific awareness with respect to basic clinical information as well as latest developments in clinical lab medicine and to promote presence of Knowledge Capital at SRL
- Translating basic research findings for diagnostic and therapeutic applications, through collaborative studies
- Obtain recognition as a National as well as International Reference Centre for carrying out clinical research and testing for few selective diseases
- Provide biological specimens/ or their derivatives for wide applications including basic research, clinical research and epidemiological studies
Emerging new technologies and tests need to be evaluated for their relevance
and feasibility without any compromise on the quality of service provided.
Hence, critical assessment of every test/technology is a prerequisite
before any implementation.
To this end, the R&D Division at SRL Ranbaxy provides support directly and indirectly through programmes of joint laboratory and health services research. It also focuses on developing clinical and research governance strategies.
| Activities at the R&D division include:
|
 |
|
In order to be on par with the latest developments in clinical testing, new test/technologies that are relevant for diagnosis/prognosis of diseases are constantly being evaluated and developed. The main focus revolves around molecular diagnostic tests involving PCR, Real Time PCR, FISH, IHC, dot-blot hybridisation assays, etc.
|
 Click the image for large view |
New Tests Developed during the Year 2005
- PCR based
- Dengue RNA PCR
- HAV PCR
- Real Time PCR
based
- MycoREAL (for Mycobacterium TB)
- Sequencing based
test
- Mycoresist (for MDR TB)
- Hematology
- Ham’s Test for PNH
- Sucrose lysis test for PNH
- Parvovirus IgG/IgM
New Tests Developed during the Year 2004
- PCR based tests:
- C-myc Amplification
- T-cell gene rearrangement
- B-cell (IgH) gene rearrangement
- Leptospirosis
- HPV 16/18 typing
- Bacterial Meningitis panel
- HLA typing by PCR
- Legionella DNA PCR
- HBV Genotyping
- Real Time PCR Assay:
- PML-RARA transcript
- Fluorescent In
Situ Hybridization (FISH)
- BCR-ABL- t (9;22)
- PML-RARA- t (15;17)
- Aneuploidy detection (13,18,21,X, Y) for POC
- HER-2/NEU for Ca Breast
- Anti CCP Antibody detection for RA
- Anti Islets antibody detection
- Maternal serum screening parameter – PAPP-A
New Tests Developed during the Year 2003.
- Viral Pneumonia panel
- Bacterial Pneumonia panel
- PCR for Corona virus
- New test for Diabetes
- Anti GAD IgG
- Anti Insulin antibodies
- HBV Real Time PCR
- HCV Real Time PCR
- BCR-ABL Real Time PCR
- Factor V Leiden mutation detection
- Factor II mutation detection
- BCL2 Real Time PCR
- PML-RaRα Real Time PCR
In keeping with its principles of providing quality and reliable diagnostic tests, SRL Ranbaxy assures that every test before being made available is validated meticulously by the R&D Division. As a unique approach, the R &D Division also strives to verify if normal ranges for the test compare with that of the Indian population, since most of the commercially available testing kits are manufactured abroad. Thus, new reference ranges are established among Indian population providing an appropriate interpretation of test results and also giving a promotional avenue for the kit's manufacturers.
Biological
specimens collected and stored in bio-repositories play a vital role in
health research. These specimens include DNA, serum/plasma, tissue blocks/slides
and pure cultures of bacteria or fungi isolated from clinical specimens.
This can be made available to researchers / organisations / institutions
as they are useful for large epidemiological studies, clinical research
studies, Quality Control (Inter-Laboratory & Intra-Laboratory) and
validation programmes.
Data obtained from
various diagnostic tests are analysed & archived. The "databank" provides
unique information about the geographical distribution pattern of genotypes,
serological markers and the seroprevalance of several diseases in India.
This can be made available to interested organisations/institutions as
these can prove to be very valuable tools for epidemiological/clinical
research studies including genomics and proteomics. Its use in New Drug
Development cannot be emphasized enough.
Currently available data : Several parameters related to HIV, Hepatitis
and Tuberculosis in Indian population.
Contract Research & Collaboration
| With its valuable assets of trained staff, sophisticated equipment and unmatched experience, SRL Ranbaxy encourages collaborations from National as well as International Agencies/Universities/Research Institutes. Current Collaborators
|
SRL
Ranbaxy's R&D Division initiates major projects through collaboration
with interested organisations. M.Sc./ Ph.D. programme / Summer projects
SRL is affiliated with MAHE ( Manipal Academy of Higher Education ) for Ph D programme. www.manipal.edu
MSc in Biotechnology (by research) at SRL Ranbaxy (recognized by the Mumbai University) for the academic year July, 2008
The program
details:
The MSc program (research) will commence on 1st, July, 2008.
Applications for the same will be accepted till 15th, May, 2008.
Interviews of shortlisted candidates will be held around first week of
June, 2008.
Eligibility:
A first class bachelor’s degree in life sciences, microbiology,
biotechnology, biochemistry, biology, bioscience, chemistry, medicine,
veterinary medicine, agriculture medicine, pharmacy, molecular biology,
genetics or a related subject.
Selection:
Candidates should therefore submit the following with their application:
A Curriculum Vitae, Two references, Photocopies of certificates and mark
sheets, Personal Statement: about 300 words explaining why the applicant
wishes to take the proposed course and how the degree might be of long
term benefit, A Research Proposal (about 1000 words) containing the following:
research topic, aims and objective, background and context, together with
a short list of key references, the value/relevance of the research, proposed
methods.
Application:
Applications should be addressed to:
Dr. B. R. Das
Executive Director – Research &Technology
Head – Molecular Diagnostics
SRL Ranbaxy Ltd.
Plot 124, 17th Street
M.I.D.C. Andheri (East) Mumbai: 400093
(Email --- brdas@srlranbaxy.co.in
).
Applications should be accompanied with a Demand Draft of Rs.500/- in
favour of “SRL RANBAXY LIMITED” payable at Mumbai.
Any queries for
consultancy on Databank, Repository, Contract research, Collaboration,
Courses, Kit validation may be addressed to:
Dr.
B.R. Das.
Executive Director- Research & Technology.
